Arena Pharmaceuticals, Inc. announced that it has amended its Belviq (lorcaserin HCl) marketing and supply agreement with Eisai Co., Ltd....
The FDA has requested that Eisai Co. Ltd. voluntarily withdraw the obesity pills Belviq and Belviq XR (lorcaserin) from the...
Eisai and Arena Pharmaceuticals have announced that the FDA has accepted for filing the New Drug Application for an extended...
Eisai announced that it has expanded the marketing and supply agreement it concluded with Arena Pharmaceuticals, Inc. in July 2010...
The FDA has approved Belviq (lorcaserin HCl), from Eisai and Arena Pharmaceuticals, as an adjunct to a reduced-calorie diet and...
Eisai and Arena Pharmaceuticals have announced that a pooled analysis of the BLOOM and BLOSSOM pivotal, Phase III clinical trials...
Eisai announced positive topline results from the CAMELLIA-TIMI 61 cardiovascular outcome trial, a 12,000 patient study of Belviq (lorcaserin HCl)...
Eisai Co., Ltd. has announced that results from the Cardiovascular Outcomes Trial (CAMELLIA-TIMI 61) in patients treated with lorcaserin hydrochloride...
Eisai and Arena Pharmaceuticals have announced that an article based on post-hoc analyses from the three pivotal Phase III trials...